Biblio

Author [ Title(Desc)] Type Year
Filters: Author is Ljungman, Per  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Wertheimer T, Dohse M, Afram G, Weber D, Heidenreich M, Holler B, Kattner A-S, Neubauer A, Mielke S, Ljungman P, et al. Abatacept as salvage therapy in chronic graft-versus-host disease-a retrospective analysis. Ann Hematol. 2021.
Dahlén T, Edgren G, Ljungman P, Flygt H, Richter J, Olsson-Strömberg U, Wadenvik H, Dreimane A, Myhr-Eriksson K, Zhao J, et al. Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study. Am J Hematol. 2022.
Maeurer M, Magalhaes I, Andersson J, Ljungman P, Sandholm E, Uhlin M, Mattsson J, Ringdén O. Allogeneic Hematopoietic Cell Transplantation for GATA2 Deficiency in a Patient With Disseminated Human Papillomavirus Disease. Transplantation. 2014;98(12):e95-e96.
Wedge E, Hansen JWerner, Dybedal I, Creignou M, Ejerblad E, Lorenz F, Werlenius O, Ungerstedt J, Holm MSkov, Nilsson L, et al. Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: Clinical and molecular genetic prognostic factors in a Nordic population. Transplant Cell Ther. 2021.
Radujkovic A, Dietrich S, Blok H-J, Nagler A, Ayuk F, Finke J, Tischer J, Mayer J, Koc Y, Sorà F, et al. Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors - A retrospective study by the EBMT Chronic Malignancies Working Party. Biol Blood Marrow Transplant. 2019.